Renal amyloidosis: Pathogenesis

2021 ◽  
pp. 1-9
Author(s):  
Guillermo A. Herrera
Keyword(s):  
Renal Amyloidosis

scholarly journals Repeat exit site infection in peritoneal dialysis patient with polycythemia vera – a case report

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Edyta Gołembiewska ◽  
Kazimierz Ciechanowski
Keyword(s):  
Pseudomonas Aeruginosa ◽  
Peritoneal Dialysis ◽  
Case Report ◽  
Polycythemia Vera ◽  
Significant Risk ◽  
Renal Amyloidosis ◽  
Site Infection ◽  
Exit Site ◽  
Exit Site Infection ◽  
First Case

Abstract Background Infectious complications of peritoneal dialysis (PD) remain a common cause of catheter loss and discontinuation of PD. Exit site infection (ESI) constitutes a significant risk factor for PD-related peritonitis and determination of predisposing states is relevant. We here present a case of repeat ESI due to Pseudomonas aeruginosa in a PD patient with skin changes in the course of polycythemia vera (PV). Case presentation A 73-year-old PD patient with chronic kidney disease secondary to renal amyloidosis and ankylosing spondylitis, presented to the nephrology unit with signs of ESI. In 2006 he was diagnosed with PV and since then has was successfully treated with hydroxyurea; however, he reported recurrent episodes of developing skin nodules in the course of the disease. Exit site swab yielded Pseudomonas aeruginosa and the infection developed in the ulcerated PV nodule that appeared in exit site 2 weeks earlier. Patient was treated with intraperitoneal amikacin and oral ciprofloxacin, however, due to neurological complications, the treatment had to be interrupted and finally catheter was removed. Similar episode of ESI with Pseudomonas aeruginosa developed in the patient two years earlier and also required catheter removal. Conclusion This is the first case report demonstrating the development of ESI on the polycythemia vera skin lesion in this area. Skin manifestations of PV might be a predisposing factor to ESI in PD patients.

scholarly journals POS-472 EPIDEMIOLOGY AND CLINICAL PROFILE OF RENAL AMYLOIDOSIS: SINGLE-CENTER EXPERIENCE

2021 ◽  
Vol 6 (4) ◽  
pp. S205
Author(s):  
A. AYED ◽  
M. Ben Salem ◽  
A. Letaief ◽  
M. Ben Saleh ◽  
M. Hammouda ◽  
...  
Keyword(s):  
Clinical Profile ◽  
Renal Amyloidosis ◽  
Single Center ◽  
Single Center Experience

Spontaneous Glomerulonephritis in Dogs: II. Correlation of Glomerulonephritis with Age, Chronic Interstitial Nephritis and Extrarenal Lesions

1977 ◽  
Vol 14 (2) ◽  
pp. 121-127 ◽  
Author(s):  
R. Müller-Peddinghaus ◽  
G. Trautwein
Keyword(s):  
Interstitial Nephritis ◽  
Membranoproliferative Glomerulonephritis ◽  
Age Groups ◽  
Renal Amyloidosis ◽  
Morphologic Study ◽  
Different Types ◽  
End Stage ◽  
Chronic Interstitial Nephritis ◽  
Slight Damage ◽  
Severe Fibrosis

A morphologic study of 103 dogs, including two with renal amyloidosis, showed that different types of diffuse glomerulonephritis are correlated with different age groups. Membranous and membranoproliferative glomerulonephritis were more common in middle-aged and older animals, whereas mesangial lesions were found predominantly in younger dogs and considered to be early glomerular changes. Glomerulonephritis largely occurred independently of interstitial nephritis. The incidence of interstitial lesions was 71%. Chronic interstitial nephritis was rare in dogs under 1 year old. Glomerulonephritis did not seem to induce interstitial nephritis. Glomerulonephritis occurred not only in kidneys with severe interstitial damage, but also in those with slight damage. This indicated that glomerulonephritis occurred independently of interstitial nephritis. In end-stage kidneys with severe fibrosis, mesangial changes seemed to predominate.

Quantitative Analysis of Interstitial Mast Cells in AA and AL Renal Amyloidosis

2002 ◽  
Vol 198 (6) ◽  
pp. 413-419 ◽  
Author(s):  
Marian Danilewicz ◽  
Małgorzata Wągrowska-Danilewicz
Keyword(s):  
Quantitative Analysis ◽  
Mast Cells ◽  
Renal Amyloidosis

RENAL AMYLOIDOSIS RESULTING FROM A CHRONICALLY INFECTED BURN

PEDIATRICS ◽  
1963 ◽  
Vol 32 (5) ◽  
pp. 888-894
Author(s):  
Saul Hoffman ◽  
Bernard E. Simon ◽  
Robert A. Fischel ◽  
Donald Gribetz
Keyword(s):  
Nephrotic Syndrome ◽  
Renal Biopsy ◽  
Clinical Improvement ◽  
Short Duration ◽  
Unusual Case ◽  
White Male ◽  
Lower Extremities ◽  
Renal Amyloidosis ◽  
One Year

An interesting and unusual case of an 11-year-old white male with chronically infected burns of his lower extremities who developed amyloidosis and the nephrotic syndrome is reported. The case is considered from the following aspects: (1) the rarity of amyloidosis in burns, (2) the short duration between the onset of the primary disease and the amyloidosis, (3) the age of the patient, and (4) the striking clinical improvement of the renal manifestations after the treatment of the burn. The treatment of the burns, using homografts, and the importance of renal biopsy in the diagnosis and follow-up are also discussed. Addendum: A third renal biopsy was performed in August, 1963, about one year following the second one. The amount of amyloid seen in the glomeruli did not seem to have diminished.

scholarly journals Rituximab Therapy in Renal Amyloidosis Secondary to Rheumatoid Arthritis

Biomolecules ◽  
2018 ◽  
Vol 8 (4) ◽  
pp. 136 ◽  
Author(s):  
Levent Kilic ◽  
Abdulsamet Erden ◽  
Yusuf Sener ◽  
Berkan Armagan ◽  
Alper Sari ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Clinical Improvement ◽  
Inflammatory Diseases ◽  
Case Series ◽  
New Drugs ◽  
Renal Amyloidosis ◽  
Secondary Amyloidosis ◽  
Aa Amyloidosis ◽  
Amyloid A ◽  
Significant Clinical Improvement

Secondary amyloid A (AA) amyloidosis is a late and serious complication of poorly controlled, chronic inflammatory diseases. Rheumatoid arthritis (RA) patients with poorly controlled, longstanding disease and those with extra-articular manifestations are under risk for the development of AA amyloidosis. Although new drugs have proven to be significantly effective in the treatment of secondary AA amyloidosis, no treatment modality has proven to be ideal. To date, only in small case series preliminary clinical improvement have been shown with rituximab therapy for AA amyloidosis secondary to RA that is refractory to TNF-α inhibitors (TNF-i) therapy. In these case series, we assessed the efficacy and safety of rituximab therapy for patients with RA and secondary amyloidosis. Hacettepe University Biologic Registry was developed at 2005. The data of the RA patients who were prescribed a biological drug were recorded regularly. Patients with biopsy proven AA amyloidosis patients were screened. Of 1022 RA patients under biologic therapy, 0.7% patients had clinically apparent histologically confirmed amyloidosis. Four of seven patients who were prescribed rituximab at least one infusion enrolled to those case series. Two of four patients showed significant clinical improvement and one of them also had decrease in proteinuria and the other one had stable renal function and proteinuria. The main goal for the treatment of AA amyloidosis is to control the activity of the underlying disorder. In this study, we showed that rituximab may be an effective treatment in RA patients with amyloidosis who were unresponsive to conventional disease modifying anti-rheumatic drugs (DMARDs) and/or TNFi.

Pregnancy and nephrotic syndrome due to renal amyloidosis

1971 ◽  
Vol 111 (2) ◽  
pp. 306-307 ◽  
Author(s):  
Philip J. Feitelson ◽  
Rafael Ortiz ◽  
Marshall D. Lindheimer
Keyword(s):  
Nephrotic Syndrome ◽  
Renal Amyloidosis
Sign in / Sign up

Export Citation Format

Share Document